DOI QR코드

DOI QR Code

Effects of Sodium Valproate on the Growth of Human Ovarian Cancer Cell Line HO8910

  • Yan, Hong-Chao (Department of Obstetrics and Gynecology, the Affiliated Hospital of Xuzhou Medical College) ;
  • Zhang, Jie (Department of Obstetrics and Gynecology, the Affiliated Hospital of Xuzhou Medical College)
  • Published : 2012.12.31

Abstract

To explore a possible new treatment for human ovarian cancer, we studied the effects of sodium valproate on the growth of the HO8910 human cell line. HO8910 cells were cultured in vitro and treated with different concentrations of sodium valproate. Cell proliferation, cell cycling, and apoptosis were measured by flow cytometry, cell morphology under a microscope, and expression levels of WWOX and P27 by Western blotting and RT-PCR. Tumor xenografts were established to determine in vivo effects of sodium valproate. Our results showed that cell proliferation was decreased with increasing concentration of sodium valproate, with features of cytoplasmic retraction and floating cells. Moreover, cell cycle analysis revealed a higher apoptosis rate and $G_0/G_1$ phase in the sodium valproate experimental group than in the control group. In addition, protein expression levels of WWOX and P27 were elevated. Importantly, sodium valproate decreased in vivo xenograft tumor burden and up-regulated WWOX and P27 expression in nude mice. In conclusion, sodium valproate might play a role in inhibition and control of ovarian cancer cell line HO8910 by inhibiting cell proliferation, interfering with the cell cycle and promoting apoptosis, so that it may be effective in the clinical treatment of ovarian cancer.

Keywords

Ovarian cancer;apoptosis;WWOX;P27;sodium valproate

References

  1. Balakin KV, Ivanenkov YA, Kiselyov AS, et al (2007). Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem, 7, 576-92. https://doi.org/10.2174/187152007781668698
  2. Blaheta RA, Nau H, Michaelis M, et al (2002). Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem, 9, 1417-33. https://doi.org/10.2174/0929867023369763
  3. Davies AN (2002). Re: Sodium valproate in cancer-related neuropathic pain. J Pain Symptom Manage, 23, 1. https://doi.org/10.1016/S0885-3924(01)00385-2
  4. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al (2008). Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev, 34, 206-22. https://doi.org/10.1016/j.ctrv.2007.11.003
  5. Dutertre M, Gratadou L, Dardenne E, et al (2010). Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer. Cancer Res, 70, 3760-70. https://doi.org/10.1158/0008-5472.CAN-09-3988
  6. Fortunati N, Bertino S, Costantino L, et al (2008). Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett, 259, 156-64. https://doi.org/10.1016/j.canlet.2007.10.006
  7. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, et al (2007). Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist, 12, 942-51. https://doi.org/10.1634/theoncologist.12-8-942
  8. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  9. Li GF, Qian TL, Li GS, et al (2012). Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. Genet Mol Res, 11, 77-86. https://doi.org/10.4238/2012.January.13.1
  10. Michaelis M, Doerr HW, Cinatl J, Jr (2007). Valproic acid as anticancer drug. Curr Pharm Des, 13, 3378-93. https://doi.org/10.2174/138161207782360528
  11. Platta CS, Greenblatt DY, Kunnimalaiyaan M, et al(2008). Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res, 148, 31-7. https://doi.org/10.1016/j.jss.2008.03.008
  12. Sami S, Hoti N, Xu HM, et al (2008). Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem, 144, 357-62. https://doi.org/10.1093/jb/mvn074
  13. Shi CW, Zhao X, Cao LL, et al (2007). Effect of valproate acid sodium on apoptosis of human gastric cancer cells and its mechanism study. Zhonghua Wei Chang Wai Ke Za Zhi, 10, 468-71.
  14. Takai N, Desmond JC, Kumagai T, et al (2004). Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res, 10, 1141-9. https://doi.org/10.1158/1078-0432.CCR-03-0100
  15. Tryfon S, Saroglou M, Kazanas K, et al (2009). Sodium valproate as a cause of recurrent transudative pleural effusion: a case report. J Med Case Rep, 3, 51. https://doi.org/10.1186/1752-1947-3-51
  16. Venugopal B, Evans TR (2011). Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem, 18, 1658-71. https://doi.org/10.2174/092986711795471284

Cited by

  1. WW domain-containing oxidoreductase’s role in myriad cancers: Clinical significance and future implications vol.239, pp.3, 2014, https://doi.org/10.1177/1535370213519213
  2. Ectopic expression of the WWOX gene suppresses stemness of human ovarian cancer stem cells pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.2971
  3. Proliferation inhibition of cisplatin-resistant ovarian cancer cells using drugs screened by integrating a metabolic model and transcriptomic data vol.50, pp.6, 2017, https://doi.org/10.1111/cpr.12370
  4. Evaluation of the mechanism of epithelial-mesenchymal transition in human ovarian cancer stem cells transfected with a WW domain-containing oxidoreductase gene vol.8, pp.1, 2014, https://doi.org/10.3892/ol.2014.2063